These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32699675)

  • 1. Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States.
    Sheth N; Osborn V; Lee A; Schreiber D
    Cureus; 2020 Jun; 12(6):e8675. PubMed ID: 32699675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
    Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
    J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
    Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
    Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma.
    Liu F; Brown DR; Munley MT
    Radiother Oncol; 2024 May; 194():110223. PubMed ID: 38467342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization.
    Lee HL; Tsai JT; Chen CY; Lin YC; Ho CB; Ting LL; Kuo CC; Lai IC; Lin CY; Tang JH; Huang YM; Kao WY; Cheng SW; Shen CN; Chen SW; Chiou JF
    Ther Adv Med Oncol; 2019; 11():1758835919889002. PubMed ID: 31839809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.
    Verma V; Hasan S; Wegner RE; Abel S; Colonias A
    Radiother Oncol; 2019 Feb; 131():145-149. PubMed ID: 30773182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival.
    Robbins JR; Schmid RK; Hammad AY; Gamblin TC; Erickson BA
    Cancer Med; 2019 Mar; 8(3):928-938. PubMed ID: 30701703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
    Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
    Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
    Abel S; Hasan S; Verma V; Weksler B; Colonias A; Horne ZD; Wegner RE
    Lung Cancer; 2019 Sep; 135():169-174. PubMed ID: 31446991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience.
    Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S
    Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
    Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
    Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
    Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
    J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm.
    Guarneri A; Franco P; Trino E; Campion D; Faletti R; Mirabella S; Gaia S; Ragona R; Diotallevi M; Saracco G; Salizzoni M; Ricardi U; Carucci P
    Med Oncol; 2016 Oct; 33(10):104. PubMed ID: 27566310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
    Liu HY; Lee YD; Sridharan S; Choong ES; Le H; Wang W; Khor R; Chu J; Oar A; Mott R; Smart J; Jenkins T; Anderson N; Cross S; Loo KF; Wigg A; Stuart K; Pryor D
    J Med Imaging Radiat Oncol; 2021 Jun; 65(3):365-373. PubMed ID: 33890425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.